PMID- 29702496
OWN - NLM
STAT- MEDLINE
DCOM- 20190524
LR  - 20210109
IS  - 1531-6963 (Electronic)
IS  - 1040-8711 (Linking)
VI  - 30
IP  - 4
DP  - 2018 Jul
TI  - Quantifying the genetic risk for the development of axial spondyloarthropathy: 
      could this become a diagnostic tool?
PG  - 319-323
LID - 10.1097/BOR.0000000000000517 [doi]
AB  - PURPOSE OF REVIEW: To assess the utility of recent genetic findings in ankylosing 
      spondylitis (AS) and axial spondyloarthropathy (SpA) in relation to diagnostic 
      testing, prognosis and responses to biologic treatment and the development of new 
      therapies. RECENT FINDINGS: AS and other forms of SpA are polygenic with more 
      than 100 genes contributing to disease susceptibility. The role of genes in 
      determining the outcome of the disease and response to treatment is less clear. 
      Here, we review some of the progress that has been made over the past decade in 
      understanding the genetic contribution to these diseases and how this may be used 
      to inform the development of new treatments. In those with a high pretest 
      probability of SpA human leukocyte antigen (HLA)-B27 testing can increase the 
      posttest predictive value to almost 100% in some cases. There are currently no 
      reliable genetic predictors of disease severity or response to treatment. 
      SUMMARY: The utility of HLA-B27 as a diagnostic tool when coupled with careful 
      clinical assessment is well established but other genetic markers probably have 
      relatively little to add. In contrast, novel drug targets are likely to be 
      identified from genetic association studies.
FAU - Wordsworth, Bryan P
AU  - Wordsworth BP
AD  - Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, 
      Institute of Musculoskeletal Sciences, Botnar Research Centre, University of 
      Oxford, Oxford, UK.
FAU - Cohen, Carla J
AU  - Cohen CJ
FAU - Vecellio, Matteo
AU  - Vecellio M
LA  - eng
GR  - 19356/VAC_/Versus Arthritis/United Kingdom
GR  - 20796/ARC_/Arthritis Research UK/United Kingdom
GR  - 21428/ARC_/Arthritis Research UK/United Kingdom
GR  - 21428/VAC_/Versus Arthritis/United Kingdom
GR  - 20796/VAC_/Versus Arthritis/United Kingdom
GR  - 20773/ARC_/Arthritis Research UK/United Kingdom
GR  - 18797/ARC_/Arthritis Research UK/United Kingdom
GR  - 19536/ARC_/Arthritis Research UK/United Kingdom
GR  - 20773/VAC_/Versus Arthritis/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United States
TA  - Curr Opin Rheumatol
JT  - Current opinion in rheumatology
JID - 9000851
RN  - 0 (Genetic Markers)
RN  - 0 (HLA-B27 Antigen)
SB  - IM
MH  - Genetic Markers/genetics
MH  - HLA-B27 Antigen/*genetics
MH  - Humans
MH  - Risk Factors
MH  - Spondylarthropathies/*diagnosis/genetics
EDAT- 2018/04/28 06:00
MHDA- 2019/05/28 06:00
CRDT- 2018/04/28 06:00
PHST- 2018/04/28 06:00 [pubmed]
PHST- 2019/05/28 06:00 [medline]
PHST- 2018/04/28 06:00 [entrez]
AID - 10.1097/BOR.0000000000000517 [doi]
PST - ppublish
SO  - Curr Opin Rheumatol. 2018 Jul;30(4):319-323. doi: 10.1097/BOR.0000000000000517.